Agri Articles
(e-Magazine for Agricultural Articles)
Volume: 06, Issue: 04 (JULY-AUG, 2026)
Available online at http://www.agriarticles.com
©Agri Articles, ISSN: 2582-9882

How CRISPR is Changing the Future of Medicine

*Aiesha Dandangi
Student, Fishery Science, College of Fishery Science, Narasapuram
*Corresponding Author's email: aieshadandangi3@gmail.com

CRISPR-Cas9 has moved gene editing from a slow, expensive laboratory technique to a precise, programmable tool that is reshaping biology and medicine. Originally discovered as a bacterial immune defense mechanism against viruses, CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) now allows scientists to cut, edit, or replace specific DNA sequences with remarkable accuracy.

Before CRISPR, gene editing relied on tools such as zinc-finger nucleases and TALENs, which required painstaking, custom-built proteins for every new DNA target. This made early genome-editing projects slow, costly, and largely confined to well-funded laboratories. The discovery that the CRISPR-Cas9 system could be reprogrammed simply by changing a short guide RNA sequence, rather than re-engineering an entire protein, transformed gene editing into a tool accessible to labs worldwide, dramatically accelerating the pace of genetic research.

Since its adaptation for genome editing in 2012, CRISPR has expanded far beyond its original bacterial context, becoming a foundational technology across medicine, agriculture, and basic science. Its impact was formally recognized in 2020, when Jennifer Doudna and Emmanuelle Charpentier were awarded the Nobel Prize in Chemistry for developing the CRISPR-Cas9 genome-editing method. Today, CRISPR-based therapies are already reaching patients, and the technology continues to evolve through refinements such as base editing and prime editing, which promise even greater precision for treating human disease.

How CRISPR Works

CRISPR-Cas9 functions like a molecular pair of scissors guided by GPS. It uses three core components:

- **Guide RNA (gRNA)** – a short RNA sequence designed to match a specific target gene.
- **Cas9 enzyme** – a protein that cuts the DNA at the location specified by the guide RNA.
- **Repair mechanisms** – the cell's own repair systems then fix the cut, either disabling the gene or allowing scientists to insert a new sequence.

This simplicity, compared to older gene-editing tools like TALENs and zinc-finger nucleases, is why CRISPR has spread rapidly across research fields, including bioinformatics, where computational tools are used to design guide RNAs and predict off-target effects.



Figure 1: Simplified mechanism of CRISPR-Cas9 gene editing

Applications of CRISPR

- **Treatment of genetic diseases –** CRISPR has enabled therapies for previously untreatable inherited conditions. Sickle cell disease and beta-thalassemia are now treated using CRISPR-edited stem cells, with Casgevy marking the first approved CRISPR-based clinical therapy.
- **Cancer therapy –** researchers use CRISPR to engineer immune cells (CAR-T cells) that more effectively recognize and destroy cancer cells, improving precision beyond conventional chemotherapy. CRISPR is also used to knock out genes that allow tumors to evade the immune system, and to screen genomes for cancer-driving mutations.
- **Infectious disease diagnostics –** CRISPR-based diagnostic platforms (such as SHERLOCK and DETECTR) allow rapid, accurate detection of viral infections, a technique that gained global attention during COVID-19 testing efforts.
- **Prevention of inherited disorders –** research into germline editing raises the possibility of correcting disease-causing mutations before birth, though this application remains ethically and legally restricted in most countries.
- **Agricultural and biological research –** beyond clinical medicine, CRISPR is widely applied in crop and animal genetics to improve disease resistance, growth traits, and yield, supported by bioinformatics tools such as sequence alignment and off-target prediction software.
- **Personalized and precision medicine –** CRISPR-based screening allows researchers to study how individual genetic variants affect drug response, enabling therapies tailored to a patient's genome and accelerating pharmacogenomics.
- **Drug discovery and development –** pharmaceutical companies use CRISPR screens to identify new drug targets by systematically switching genes on or off across thousands of cells, shortening timelines for diseases such as cancer, diabetes, and neurodegenerative disorders.
- **Regenerative medicine and organ transplantation –** CRISPR is used to edit pig genomes, removing genes that trigger immune rejection, to make xenotransplantation safer and more viable, and alongside stem cell technology to repair damaged tissue.
- **Neurological and rare diseases –** emerging CRISPR therapies target conditions like Huntington's disease, Duchenne muscular dystrophy, and inherited blindness. In vivo editing is a major area of current clinical trial activity.

Advantages and Disadvantages

Advantages of CRISPR

- **High precision –** targets specific DNA sequences with far greater accuracy than earlier gene-editing methods.
- **Low cost and speed –** cheaper and faster to design and implement than TALENs or zinc-finger nucleases, accelerating research timelines.
- **Versatility –** applicable across human medicine, agriculture, and basic research, from single-gene disorders to genome-wide screens.
- **One-time treatment potential –** some therapies (e.g., for sickle cell disease) offer a lasting cure from a single treatment rather than lifelong management.
- **Improved diagnostics –** enables rapid, sensitive detection of pathogens, useful during disease outbreaks.
- **Continuous refinement –** newer tools like base editing and prime editing are steadily reducing risk and improving accuracy.

Disadvantages of CRISPR

- **Off-target effects –** unintended edits elsewhere in the genome can potentially cause new mutations or health risks.
- **Delivery challenges –** safely and efficiently delivering CRISPR components into the right cells in the body remains technically difficult.

- **High treatment cost –** current approved therapies cost hundreds of thousands of dollars, limiting accessibility for most patients.
- **Ethical concerns –** germline editing raises concerns about permanent, heritable changes to the human gene pool and potential misuse for non-therapeutic enhancement.
- **Limited long-term data –** as a relatively new clinical technology, the long-term safety and durability of CRISPR treatments are still being studied.
- **Regulatory and legal uncertainty –** laws around gene editing vary widely between countries, complicating research and treatment access.
- **Ecological risk –** gene-edited organisms released into the environment could have unintended effects on ecosystems.

Future Prospects

Ongoing research is pushing CRISPR toward greater precision and safety. Newer variants such as base editing and prime editing allow single-letter DNA changes without cutting both strands of the double helix, reducing the risk of unintended mutations. As delivery systems improve and costs decrease, CRISPR is expected to move from treating rare, single-gene disorders toward more common conditions, potentially transforming how diseases like heart disease, diabetes, and even aging-related decline are approached in the coming decades.

Conclusion

CRISPR represents one of the most significant advances in modern biotechnology. Its advantages in precision, speed, and versatility are already producing real clinical breakthroughs, while its disadvantages — cost, safety unknowns, and ethical complexity — highlight why careful regulation and continued research remain essential. As bioinformatics continues to refine the precision and safety of gene editing, CRISPR's role will likely expand from treating rare disease to broader applications across medicine, making it a cornerstone technology for the future of healthcare.

References

1. Anzalone, A. V., Koblan, L. W., & Liu, D. R. (2020). Genome editing with CRISPR–Cas nucleases, base editors, transposases and prime editors. *Nature Biotechnology, 38*(7), 824–844. https://doi.org/10.1038/s41587-020-0561-9
2. Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. *Science, 346*(6213), 1258096. https://doi.org/10.1126/science.1258096
3. U.S. Food and Drug Administration. (2023). *FDA approves first gene therapies to treat patients with sickle cell disease* [Press release]. https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease
4. Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA–guided DNA endonuclease in adaptive bacterial immunity. *Science, 337*(6096), 816–821. https://doi.org/10.1126/science.1225829
5. Kellner, M. J., Koob, J. G., Gootenberg, J. S., Abudayyeh, O. O., & Zhang, F. (2019). SHERLOCK: nucleic acid detection with CRISPR nucleases. *Nature Protocols, 14*(10), 2986–3012. https://doi.org/10.1038/s41596-019-0210-2
6. National Human Genome Research Institute. (2024). *What is genome editing?* National Institutes of Health. https://www.genome.gov/about-genomics/policy-issues/what-is-Genome-Editing
7. The Royal Swedish Academy of Sciences. (2020). *The Nobel Prize in Chemistry 2020: Press release*. NobelPrize.org. https://www.nobelprize.org/prizes/chemistry/2020/press-release/